Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Cagrilintide
Advertisement
Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity
COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...
Novo Nordisk’s CagriSema Delivers Strong HbA1c and Weight Loss Results in Phase 3 REIMAGINE Trials
Plainsboro, New Jersey and Bagsværd, Denmark, June 7, 2026 Novo Nordisk has unveiled compelling Phase 3 clinical data for...
Advertisement
